Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its target price reduced by Royal Bank of Canada from $12.00 to $10.00 in a report released on Tuesday, Benzinga reports. They currently have a sector perform rating on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the company. Truist Financial […]